Cover Image

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers

Chungam Choi,1 Byung Won Yoo,2 Choon Ok Kim,2 Taegon Hong,2 Byung Hak Jin,2 Kwang-Seok Seo,3 Ja Yun Jang,4 Min Soo Park2 1Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; 2Department of Clinical Pharmacology, Severance Hospital, Yonsei Un...

Full description

Saved in:

Bibliographic Details
Main Authors:	Choi C (Author), Yoo BW (Author), Kim CO (Author), Hong T (Author), Jin BH (Author), Seo KS (Author), Jang JY (Author), Park MS (Author)
Format:	Book
Published:	Dove Medical Press, 2018-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
by: Igor Makarenko, et al.
Published: (2023)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
by: Lee J, et al.
Published: (2014)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
by: Gu N, et al.
Published: (2014)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
by: Kim D, et al.
Published: (2019)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
by: Shin Y, et al.
Published: (2022)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
by: Jang K, et al.
Published: (2017)

Study of GABA in healthy volunteers: pharmacokinetics and pharmacodynamics
by: Junfeng eLi, et al.
Published: (2015)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018)

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
by: Deok Y. Yoon, et al.
Published: (2021)

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
by: Yoon S, et al.
Published: (2014)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
by: Choi Y, et al.
Published: (2018)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
by: Hwang I, et al.
Published: (2020)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
by: B Wang, et al.
Published: (2017)

The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers
by: Guojing Liu, et al.
Published: (2016)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
by: Hong T, et al.
Published: (2015)

Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
by: Shijia Liu, et al.
Published: (2017)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
by: Nagelschmitz J, et al.
Published: (2014)

Population Pharmacokinetic and Pharmacodynamic Modeling of Acetazolamide in Peritoneal Dialysis Patients and Healthy Volunteers
by: Corinne Seng Yue, et al.
Published: (2013)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
by: Hanjing Chen, et al.
Published: (2022)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
by: Yu-Jeong Son, et al.
Published: (2023)

Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
by: Del Tacca M, et al.
Published: (2013)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
by: Huijun Chen, et al.
Published: (2024)

Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers
by: Keisuke Motoki, et al.
Published: (2019)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
by: Mohammad Al‐Mahdi Al‐Karagholi, et al.
Published: (2021)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
by: Rhee SJ, et al.
Published: (2016)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019)

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Hendrik Wessels, et al.
Published: (2019)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019)

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers
by: Kim YH, et al.
Published: (2015)

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers
by: Xinwen Wang, et al.
Published: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics
by: Bianca Vora, et al.
Published: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
by: Joseph F. Grippo, et al.
Published: (2021)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
by: Yoon S, et al.
Published: (2015)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
by: Kim E, et al.
Published: (2019)